NCT03934307 - A Study to Evaluate ALN-AGT01 in Patients With Hypertension | Biotech Hunter

Enrollment

124

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

April 20, 2022

Study Completion Date

January 4, 2023

Conditions

Hypertension

Interventions

DRUG

ALN-AGT01

ALN-AGT01 will be administered by subcutaneous (SC) injection.

DRUG

ALN-AGT01-Matching Placebo

Normal saline (0.9% NaCl) matching volume of ALN-AGT01 doses will be administered SC.

DRUG

Irbesartan

Irbesartan will be administered orally.

DRUG

Irbesartan-Matching Placebo

Irbesartan-matching placebo will be administered orally.

Trial Locations (3)

Clinical Trial Site, Edinburgh

Clinical Trial Site, London

Clinical Trial Site, Manchester